title: FCR holds up to the test of time: CLL8 follow-up.
authors.affiliation: THE OHIO STATE UNIVERSITY.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Woyach
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D008297:Male; D000069283:Rituximab / Q000008:administration & dosage*; D014740:Vidarabine / Q000031:analogs & derivatives*
chemical_list: D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine